Transcript Slide 1
Business Plan Presentation & Pitching Jonas CT, Wang Ph. D. Partners, Sycamore Ventures December 4, 2004 Jonas CT, Wang Ph. D Partner, SYCAMORE VENTURES • National Defense Medical Center, Taipei Taiwan ROC, 1967 (The 2nd Military Medical University, Shanghai PROC) • Instructor, School of Pharmacy NDMC Taiwan ROC 1968-1977 • Ph. D. College Of Pharmacy, University of Iowa, 1982 • Associate Director, Bristol-Myers-Squibb, 1981-1988 • Vice President, Research & Technology RD&E Division Johnson & Johnson Consumer Products WW 1988-2001 • CEO/President, StemCyte Inc., July-October 2002 • Partner, Sycamore Ventures 2001-Present • Fields of Expertise: Technology & Business Strategy, IP Strategy, and Global market development strategy, in Pharmaceuticals & Biotechnology. Venture Capital Firms Looking For Plan B "The Pink Sheet", January 05, 2009 Copyright FDC Reports Inc. 2009 ● ● ● ● ● ● Companies are cheap, but money is expensive. Burn must be slowed, but without sacrificing value drivers. Finding the exit has never been more difficult. A devastating fund-raising environment-a dilemma: the ongoing financial crisis means there are buying opportunities for VCs with cash, but it also means fewer total dollars going into VC funds. Because of the financial meltdown, straitened endowments and institutions will have less to invest in venture capital in 2009, making it one of the most difficult fund-raising environments in memory. Even already committed capital may be at risk; despite evidence to the contrary, rumors are spreading that certain limited partners are balking on capital calls. Sample of Investment Proposal Memo I. Recommendation Amount and instrument IRR Closing Date II. Background…………………………………(History) III. Product & Services……………………….. (Technology) IV. Market Size & Growth Rate………………(Marketing) Competitions Accessible Market V. Management Team…………………………(Management) VI. Financial History & Projections…………..(Finance) Shareholder List Income Statements, Balance Sheets, Cash Flows Comparables & IRR VII. Sources & Uses of Fund……………………(F & M) VIII. Rationale for the Investment………………(Justification) IX. Risks…………………………………………(Legal) X. Outstanding Issues………………………….(Concerns) XI. Appendix Due Diligences……………………..(Communication)